Key Takeaways
- • Biopharma hedge funds posted double-digit gains in June 2026, with the Nasdaq Biotechnology Index rising 9.6% and the State Street SPDR S&P Biotech ETF climbing 16%, reversing year-to-date underperformance versus broad market indices.
- • AbbVie's $135.11-per-share cash acquisition of Apogee Therapeutics drove outsized returns, with Apogee shares surging 46% on June 22; the Affinity Healthcare Fund, whose largest position was Apogee, posted mid-teens June returns and 34.27% year-to-date gains.
- • M&A momentum accelerated in 2026 with $65+ billion in PLS deal value in Q1 alone—the strongest quarter since 2020—and 16 deals exceeding $1 billion, signaling sustained dealmaking as large pharmaceutical companies replenish shrinking drug pipelines.
- • Goldman Sachs identifies a "golden age" of scientific innovation, citing surging new drug approvals and forecasting continued M&A activity alongside increased IPOs of late-stage biopharma companies as capital markets rebound.
- • Biotech sector IPO activity already surpassed 2025 full-year proceeds, with six biopharma IPOs raising $1.8 billion in Q1 2026 alone, reflecting renewed investor appetite for the sector.
Summary
Biopharma-focused hedge funds delivered strong performance in June 2026, driven by blockbuster acquisition activity and renewed investor confidence in scientific breakthroughs and artificial intelligence applications within drug development. The Nasdaq Biotechnology Index rose approximately 9.6% during the month, while the State Street SPDR S&P Biotech ETF climbed more than 16%. These gains represent a significant inflection point for the sector, as most biopharma funds are now outperforming the broad market index after trailing it throughout the first half of 2026.
The Affinity Healthcare Fund emerged as the month's top performer, posting mid-teens returns for June and achieving 34.27% year-to-date gains. The fund benefited substantially from AbbVie's announced acquisition of Apogee Therapeutics for $135.11 per share in an all-cash transaction. Following the June 22 announcement, Apogee shares jumped 46% on the day. Apogee represented Affinity's largest common stock long position, accounting for more than 5% of fund assets as of the first quarter's close, directly translating to significant alpha generation.
Broader market dynamics underscore sustained momentum in biopharma dealmaking. Pharmaceutical and life sciences deal value exceeded $65 billion in Q1 2026 alone—the strongest quarter since 2020—with 16 transactions exceeding $1 billion announced in the first half. Year-to-date biotech M&A totaled $15.6 billion across 19 deals, while six biopharma IPOs raised $1.8 billion in the first quarter alone, already surpassing full-year 2025 IPO proceeds and signaling renewed institutional appetite for the sector.
Goldman Sachs Prime Insights & Analytics attributes this momentum to what it characterizes as a "golden age" of scientific innovation. The firm notes that "new drug approvals and scientific opportunities have surged as the drugs themselves become more developed" over recent decades. Goldman anticipates a continuation of heightened M&A activity as cash-rich pharmaceutical corporations pursue acquisitions to replenish depleting drug pipelines. The firm also forecasts an uptick in IPOs of late-stage biopharma companies, suggesting that favorable capital markets conditions and scientific progress will support deal flow and public market activity through the remainder of 2026.
The Affinity Healthcare Fund emerged as the month's top performer, posting mid-teens returns for June and achieving 34.27% year-to-date gains. The fund benefited substantially from AbbVie's announced acquisition of Apogee Therapeutics for $135.11 per share in an all-cash transaction. Following the June 22 announcement, Apogee shares jumped 46% on the day. Apogee represented Affinity's largest common stock long position, accounting for more than 5% of fund assets as of the first quarter's close, directly translating to significant alpha generation.
Broader market dynamics underscore sustained momentum in biopharma dealmaking. Pharmaceutical and life sciences deal value exceeded $65 billion in Q1 2026 alone—the strongest quarter since 2020—with 16 transactions exceeding $1 billion announced in the first half. Year-to-date biotech M&A totaled $15.6 billion across 19 deals, while six biopharma IPOs raised $1.8 billion in the first quarter alone, already surpassing full-year 2025 IPO proceeds and signaling renewed institutional appetite for the sector.
Goldman Sachs Prime Insights & Analytics attributes this momentum to what it characterizes as a "golden age" of scientific innovation. The firm notes that "new drug approvals and scientific opportunities have surged as the drugs themselves become more developed" over recent decades. Goldman anticipates a continuation of heightened M&A activity as cash-rich pharmaceutical corporations pursue acquisitions to replenish depleting drug pipelines. The firm also forecasts an uptick in IPOs of late-stage biopharma companies, suggesting that favorable capital markets conditions and scientific progress will support deal flow and public market activity through the remainder of 2026.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.